Lemonade
LMND
$56.00
-14.85%
Lemonade, Inc. operates as a technology-first insurance company, offering a digital and AI-powered platform for personal property and casualty insurance within the United States and Europe. The company positions itself as a disruptive force in the traditional insurance industry, leveraging artificial intelligence, contemporary design, and a direct-to-consumer model to deliver a more transparent and efficient customer experience. The current investor narrative is intensely focused on its AI-driven growth model and a recent strategic partnership, with headlines highlighting a significant stock surge following a Morgan Stanley upgrade that cited its first-mover advantage in autonomous vehicle insurance through a data-sharing deal with Tesla.…
LMND
Lemonade
$56.00
Related headlines
LMND 12-Month Price Forecast
Wall Street consensus
Most Wall Street analysts maintain a constructive view on Lemonade's 12-month outlook, with a consensus price target around $72.80 and implied upside of +30.0% versus the current price.
Average Target
$72.80
3 analysts
Implied Upside
+30.0%
vs. current price
Analyst Count
3
covering this stock
Price Range
$45 - $73
Analyst target range
Analyst coverage for Lemonade is limited, with only 3 analysts providing estimates according to the data, which is low for a public company and suggests it is still considered a niche or speculative story with limited institutional following. The consensus recommendation cannot be definitively determined from the provided ratings distribution, but recent institutional actions show a mixed picture: Morgan Stanley upgraded the stock to 'Overweight' in March 2026, while Keefe, Bruyette & Woods maintains an 'Underperform' rating. The average revenue estimate for the next period is $1.61 billion, but no average price target is provided in the data, making a calculation of implied upside or downside impossible. The target price range is also not available in the provided dataset. The limited coverage and mixed signals from recent analyst actions (an upgrade versus a maintained underperform) indicate high uncertainty and a lack of strong consensus, which is typical for a company in a transformational phase and can contribute to the stock's high volatility as new information is asymmetrically processed by the market.
Bulls vs Bears: LMND Investment Factors
The evidence currently tilts slightly bearish in the near term, given the stock's severe technical correction, high volatility, and persistent losses, which outweigh the strong fundamental growth story for risk-averse investors. However, for growth-oriented investors, the bull case is compelling, anchored by 53% revenue growth, a dramatic margin improvement trend, and a recent positive free cash flow inflection. The single most important tension in the investment debate is whether Lemonade's rapid margin improvement and path to profitability can sustainably outpace the market's patience, given its premium sales multiple. The resolution of this tension—specifically, the company's ability to achieve consistent quarterly profitability—will determine if the stock re-rates higher or faces further multiple compression.
Bullish
- Exceptional Revenue Growth Trajectory: Lemonade's Q4 2025 revenue grew 53.29% year-over-year to $228.1 million, demonstrating its ability to rapidly scale its AI-driven insurance platform. This robust top-line expansion is the core of the growth thesis, indicating strong market adoption and customer acquisition.
- Dramatic Margin Improvement & Path to Profitability: Gross margin surged to 62.95% in Q4 2025 from 26.26% in Q1 2025, signaling vastly improved underwriting efficiency and pricing power. The net margin improved to -9.51% from -41.27% over the same period, showing a clear and accelerating path toward reducing losses.
- Positive Free Cash Flow Inflection Point: The company generated $17.6 million in positive free cash flow in Q4 2025, a critical inflection from negative cash burn in prior quarters. This milestone suggests the business model is beginning to generate cash from operations, reducing future financing risk.
- Strategic AI Partnership with Tesla: The recent Morgan Stanley upgrade, citing a first-mover advantage in autonomous vehicle insurance through a data-sharing deal with Tesla, validates the long-term optionality of Lemonade's AI platform. This partnership provides a narrative catalyst that differentiates it from traditional insurers.
Bearish
- Persistent and Significant Net Losses: Despite revenue growth, the company reported a Q4 2025 net loss of $21.7 million and a trailing Return on Equity of -31.02%. Sustained unprofitability raises questions about the long-term viability of the business model and its capital intensity.
- Extreme Stock Volatility & Sharp Correction: The stock has a beta of 2.043, indicating it is over 100% more volatile than the market, and has fallen 29.53% over the last 3 months. This high volatility and recent severe correction reflect investor skittishness and the stock's speculative nature.
- Weak Liquidity & Balance Sheet Concerns: A current ratio of 0.66 indicates potential short-term liquidity strain, as current liabilities exceed current assets. While debt-to-equity is manageable at 0.34, the weak liquidity position could necessitate future capital raises if cash burn resumes.
- Limited Analyst Coverage & Mixed Sentiment: Only 3 analysts cover the stock, indicating limited institutional following and high uncertainty. Recent actions are mixed, with a Morgan Stanley upgrade countered by Keefe, Bruyette & Woods' 'Underperform' rating, showing a lack of consensus.
LMND Technical Analysis
The stock is in a volatile, long-term uptrend but has recently experienced a sharp correction. The 1-year price change of +123.66% indicates a powerful bullish trend, yet the current price of $65.71 sits at approximately 53% of its 52-week range ($27.63 to $99.9), suggesting it has retreated significantly from its highs and is now in a middle-ground consolidation phase. This positioning reflects a market digesting a massive rally and subsequent pullback, balancing optimism for the company's long-term AI story against near-term valuation concerns. Recent momentum has turned decisively negative, diverging from the strong annual trend. The 3-month price change of -29.53% and the 1-month change of -2.09% show the stock is in a pronounced short-term downtrend, with the 3-month figure indicating a severe correction. This divergence suggests a potential trend reversal or a deep, healthy pullback within a longer-term bull market, likely triggered by profit-taking after the stock's parabolic move to its 52-week high. Key technical support is the 52-week low of $27.63, while immediate resistance is the recent high of $99.9. A breakdown below the recent February low near $50 could signal a continuation of the downtrend, whereas a sustained move back above the $80 level would suggest the correction is over. The stock's beta of 2.043 indicates it is over 100% more volatile than the broader market (SPY), which is critical for risk management as it implies amplified moves in both directions, consistent with the observed price swings.
Beta
2.04
2.04x market volatility
Max Drawdown
-47.7%
Largest decline past year
52-Week Range
$28-$100
Price range past year
Annual Return
+89.7%
Cumulative gain past year
| Period | LMND Return | S&P 500 |
|---|---|---|
| 1m | -4.6% | +12.6% |
| 3m | -38.7% | +2.5% |
| 6m | -6.8% | +4.3% |
| 1y | +89.7% | +28.4% |
| ytd | -26.3% | +4.3% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
LMND Fundamental Analysis
Lemonade's revenue trajectory shows robust growth but with signs of sequential deceleration. The most recent quarterly revenue for Q4 2025 was $228.1 million, representing a strong year-over-year growth rate of 53.29%. However, examining the quarterly progression from Q1 ($151.2M) to Q4 ($228.1M) reveals growth, but the pace of sequential increases has moderated, moving from a high-growth phase to a more mature expansion stage. The company remains deeply unprofitable on a net income basis, with a Q4 2025 net loss of $21.7 million. Gross margin, however, showed significant improvement in Q4 at 62.95%, a substantial increase from 26.26% in Q1 2025, indicating better pricing power or cost management in its insurance operations. The net margin for the quarter was -9.51%, a marked improvement from -41.27% in Q1, signaling a clear and positive trajectory toward reducing losses. The balance sheet shows a manageable debt level with a debt-to-equity ratio of 0.341, but liquidity is a concern with a current ratio of 0.66, indicating potential short-term asset/liability mismatches. The company generated positive free cash flow of $17.6 million in Q4, a significant turnaround from negative FCF in prior quarters, but the trailing-twelve-month free cash flow remains negative at -$25.9 million. The negative Return on Equity of -31.02% underscores the company's current lack of profitability and the capital-intensive nature of its growth phase.
Quarterly Revenue
$228100000.0B
2025-12
Revenue YoY Growth
+0.53%
YoY Comparison
Gross Margin
+0.62%
Latest Quarter
Free Cash Flow
$-25900000.0B
Last 12 Months
Revenue & Net Income Trends (2 Years)
Revenue Breakdown
Open an Account, get $2 TSLA now!
Valuation Analysis: Is LMND Overvalued?
Given the company's consistent net losses (Net Income ≤ 0), the primary valuation metric selected is the Price-to-Sales (PS) ratio. Lemonade trades at a trailing PS ratio of 6.93 and an Enterprise Value-to-Sales (EV/Sales) of 6.55. There is no forward PE available due to ongoing losses, focusing the valuation entirely on sales multiples. Comparing to industry averages is challenging as specific sector multiples are not provided in the data, but a PS ratio near 7x is typically considered high for a financial services/insurance company, suggesting the market is pricing in significant future growth and margin expansion. Historically, the stock's own PS ratio has compressed dramatically from extreme levels. The current PS of 6.93 is near the lower end of its observable historical range, which peaked above 238x in mid-2021. This compression from speculative highs to a more grounded, albeit still premium, multiple reflects the market's shift from valuing pure growth potential to requiring a path to tangible profitability, while still granting a premium for its disruptive technology platform.
PE
-30.9x
Latest Quarter
vs. Historical
Mid-Range
5-Year PE Range -59x~-3x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
-33.7x
Enterprise Value Multiple
Investment Risk Disclosure
Financial & Operational Risks are centered on Lemonade's ongoing unprofitability and liquidity. The company's net margin was -9.51% in Q4 2025, and while improving, it remains negative. The trailing-twelve-month free cash flow is -$25.9 million, though the most recent quarter was positive. A current ratio of 0.66 signals a potential mismatch between short-term assets and liabilities, which could pressure operations if the cash flow inflection proves temporary. The business model remains capital-intensive, as evidenced by a -31.02% ROE, requiring continuous growth to justify its valuation.
Market & Competitive Risks are pronounced due to Lemonade's premium valuation and high volatility. Trading at a PS ratio of 6.93, the stock carries significant valuation compression risk if growth decelerates or the path to profitability stalls. Its beta of 2.043 means it is highly sensitive to broader market swings and sector rotations away from growth stocks. The recent news highlights its dependence on narrative-driven catalysts like the Tesla partnership; failure to monetize such opportunities could lead to sentiment reversal. As a disruptor, it also faces intense competition from both entrenched insurers and other insurtechs.
Worst-Case Scenario involves a perfect storm where growth decelerates sharply, margin improvements stall, and the broader market turns risk-off. This could trigger a flight from unprofitable growth stocks, leading to a re-rating toward its tangible book value. The chain of events might start with a disappointing earnings report showing slowing revenue growth and renewed cash burn, followed by analyst downgrades. The realistic downside could see the stock retesting its 52-week low of $27.63, representing a potential loss of approximately -58% from the current price of $65.71. The historical max drawdown of -47.7% provides a recent benchmark for severe declines.